Seminars in Hematology
Volume 45, Issue 1 , Pages 39-48, January 2008

The Role of the Immune System in Myelodysplasia: Implications for Therapy

  • Elaine M. Sloand

      Affiliations

    • Corresponding Author InformationAddress correspondence to Elaine M. Sloand, MD, National Heart Lung and Blood Institute, Hematology Branch, Building 10 CRC, 4E Room 5230, Bethesda, MD 20892.
    • ,
  • Katayoun Rezvani

National Heart Lung and Blood Institute, Hematology Branch, Bethesda, MD.

Patients with myelodysplastic syndrome (MDS) have intrinsic, usually acquired genetic defects in their hematopoietic stem cells, but some others exhibit T-cell–mediated inhibition of hematopoiesis and good responses to immunosuppression. In these cases, MDS shares a similar pathophysiology with aplastic anemia (AA). Here, we review the evidence supporting a role of the immune system in the pathophysiology of MDS and the results of clinical trials of immunosuppressive agents.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0037-1963(07)00163-1

doi:10.1053/j.seminhematol.2007.11.006

Seminars in Hematology
Volume 45, Issue 1 , Pages 39-48, January 2008

Article Tools

* Image Usage & Resolution